Market Overview

The Australia oxygen concentrator market size was USD 98.00 Million in 2024 and is projected to reach USD 189.21 Million by 2033. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2025-2033. Growth is driven primarily by increasing prevalence of respiratory diseases, advancements in oxygen therapy technology, and increased awareness of home care oxygen therapy advantages. Government initiatives, a growing geriatric population opting for reliable oxygen therapy solutions, and improved healthcare infrastructure also contribute significantly to market expansion. For details, visit the Australia Oxygen Concentrator Market https://www.imarcgroup.com/australia-oxygen-concentrator-market

How AI is Reshaping the Future of Australia Oxygen Concentrator Market:

• AI-enabled smart monitoring features allow continuous assessment of oxygen levels and device performance, enhancing patient safety and adherence.
• Government healthcare programs integrate AI to optimize home-based respiratory care delivery, improving accessibility in remote and Indigenous communities.
• AI-driven predictive analytics support early detection of respiratory distress, reducing hospitalization rates and improving patient outcomes.
• Companies are launching AI-powered portable oxygen concentrators with remote adjustment capabilities, catering to user convenience and mobility.
• AI algorithms enhance device efficiency, reducing energy consumption and operational costs for long-term users.
• AI-assisted customer support and maintenance services improve device reliability and user experience, fostering higher adoption rates.

Grab a sample PDF of this report: https://www.imarcgroup.com/australia-oxygen-concentrator-market/requestsample

Market Growth Factors

The rising prevalence of chronic respiratory diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma is a major growth driver of the Australia oxygen concentrator market. The AIHW's 2024 Burden of Disease Study highlighted an 8.5% increase in asthma's burden since 2003, ranking it the 8th highest overall. For children aged 5-14, asthma accounted for 11.9% of the total disease burden, with 12.8% among males and 10.7% among females. These respiratory conditions require long-term oxygen therapy, prompting increased demand for oxygen concentrators to manage symptoms, reduce hospitalizations, and enhance quality of life. This trend is boosted by rising awareness and preference for portable and stationary concentrators for home use.

Australia's aging population significantly contributes to the oxygen concentrator market growth. Statistics from the Centre for Population indicate that by 2064–65, nearly 25% of Australians will be aged 65 and above. Age-related respiratory illnesses such as COPD and emphysema become more prevalent with this demographic shift, increasing the need for reliable, home-based oxygen therapy solutions. Government reforms targeting aged care and Indigenous health support this trend by improving affordability and availability of oxygen concentrators. Elderly patients prefer devices that allow them to manage respiratory conditions conveniently at home, reducing hospital visits and improving life quality, thus driving market demand substantially.

Environmental factors and regional vulnerabilities also stimulate the market growth. Australia frequently experiences environmental hazards like bushfires, dust storms, and high pollen seasons, especially in regions such as New South Wales, Victoria, and Western Australia. These events worsen air quality and exacerbate respiratory issues, leading to spikes in hospitalizations and increased recognition of home-based respiratory therapy needs. Portable oxygen concentrators provide timely and stable therapy to chronic respiratory patients and vulnerable groups during such environmental exposures. Moreover, Australia's geographical isolation and remote communities require accessible homecare solutions that oxygen concentrators can fulfill, bolstered by increasing awareness of climate-related respiratory health risks.

Market Segmentation

Type Insights:

• Portable
• Stationary

Technology Insights:

• Continuous Flow
• Pulse Flow

Application Insights:

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Respiratory Distress
• Others

End User Insights:

• Hospitals and Clinics
• Home Care Settings
• Ambulatory Surgical Centers and Physician Offices

Regional Insights:

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Recent Development & News

• October 2025: The Australian government collaborated with healthcare providers to expand educational programs on home oxygen therapy, aiming to improve disease management accessibility for remote and Indigenous populations, supported by increased funding for oxygen concentrator subsidies.
• August 2025: A leading oxygen concentrator manufacturer launched a campaign introducing lightweight, AI-enhanced portable devices with extended battery life and smart monitoring features, targeting mobile and elderly users, thereby enhancing product availability across Australia.
• June 2025: New market data reported a significant rise in portable oxygen concentrator adoption in regional areas, driven by worsening air quality due to environmental hazards, fueling demand for home-based respiratory care solutions and government-backed support programs.

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

https://www.imarcgroup.com/request?type=report&id=33704&flag=F

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302